Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor-targeted therapy

Human Pathology

Volumn 45, Issue 7, 2014, Pages 1437-1444

  Park, Ji Young ^a   Lee, Jae Lyun ^a   Baek, Seunghee ^a   Eo, Soo Heang ^b   Go, Heounjeong ^a   Ro, Jae Y ^c   Cho, Yong Mee ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Korea University   (South Korea)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Clinicopathological factors; Metastatic clear cell renal cell carcinoma; Prognosis; Tyrosine kinase inhibitors; Vascular endothelial growth factor

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VASCULOTROPIN;

ADRENAL METASTASIS; ADULT; AGED; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CONFERENCE PAPER; DISEASE COURSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPERCALCEMIA; IMMUNOTHERAPY; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; METASTATIC CLEAR CELL RENAL CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; NEUTROPHILIA; OSTEOSARCOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SARCOMATOID CARCINOMA; THROMBOCYTOSIS; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR NECROSIS; VERY ELDERLY;

CLINICOPATHOLOGICAL FACTORS; METASTATIC CLEAR CELL RENAL CELL CARCINOMA; PROGNOSIS; TYROSINE KINASE INHIBITORS; VASCULAR ENDOTHELIAL GROWTH FACTOR;

ADULT; AGED; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NECROSIS; NEOPLASM GRADING; PROGNOSIS; PROTEIN KINASE INHIBITORS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84903219970     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2014.02.019     Document Type: Conference Paper

References (26)

1. B.I. Rini Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma Cancer 115 2009 2306 2312
2. B.I. Rini, S.C. Campbell, and B. Escudier Renal cell carcinoma Lancet 373 2009 1119 1132
3. G. Di Lorenzo, C. Porta, and J. Bellmunt et al. Toxicities of targeted therapy and their management in kidney cancer Eur Urol 59 2011 526 540
4. D.Y. Heng, W. Xie, and M.M. Regan et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794 5799
5. D.Y. Heng, W. Xie, and M.M. Regan et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study Lancet Oncol 14 2013 141 148
6. E.A. Eisenhauer, P. Therasse, and J. Bogaerts et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
7. J.N. Eble, J.I. Epstein, and I.A. Sesterhenn World Health Organization classification of tumors 2004 IARC Press Lyon
8. S.A. Fuhrman, L.C. Lasky, and C. Limas Prognostic significance of morphologic parameters in renal cell carcinoma Am J Surg Pathol 6 1982 655 663 (Pubitemid 13234762)
9. B. Delahunt, J.C. Cheville, and G. Martignoni et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters Am J Surg Pathol 37 2013 1490 1504
10. N. Gokden, O. Nappi, and P.E. Swanson et al. Renal cell carcinoma with rhabdoid features Am J Surg Pathol 24 2000 1329 1338
11. D.C. Cho Prognostic biomarkers for patients with advanced renal cell carcinoma treated with VEGF-targeted tyrosine kinase inhibitors Onco Targets Ther 6 2013 679 684
12. A.R. Golshayan, S. George, and D.Y. Heng et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy J Clin Oncol 27 2009 235 241
13. I. Park, Y.M. Cho, and J.L. Lee et al. Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component J Cancer Res Clin Oncol 139 2013 817 827
14. A.M. Molina, S.K. Tickoo, and N. Ishill et al. Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease Am J Clin Oncol 34 2011 454 459
15. B. Delahunt Sarcomatoid renal carcinoma: the final common dedifferentiation pathway of renal epithelial malignancies Pathology 31 1999 185 190 (Pubitemid 29417595)
16. F. De Vincenzo, P.A. Zucali, and G.L. Ceresoli et al. Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma J Clin Oncol 29 2011 e529 e531
17. A. Kapoor, R. Tutino, and A. Kanaroglou et al. Treatment of adult rhabdoid renal cell carcinoma with sorafenib Can Urol Assoc J 2 2008 631 634
18. H.J. Hammers, H.M. Verheul, and B. Salumbides et al. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study Mol Cancer Ther 9 2010 1525 1535
19. S. Shimizu, Y. Eguchi, and W. Kamiike et al. Induction of apoptosis as well as necrosis by hypoxia and predominant prevention of apoptosis by Bcl-2 and Bcl-XL Cancer Res 56 1996 2161 2166
20. R. Bos, P. van der Groep, and A.E. Greijer et al. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma Cancer 97 2003 1573 1581 (Pubitemid 36297788)
21. Q.T. Le, N.C. Denko, and A.J. Giaccia Hypoxic gene expression and metastasis Cancer Metastasis Rev 23 2004 293 310 (Pubitemid 38881813)
22. L. Harrison, and K. Blackwell Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 9 Suppl 5 2004 31 40 (Pubitemid 39658343)
23. B. Escudier, T. Eisen, and W.M. Stadler et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 2009 3312 3318
24. H.T. Tran, Y. Liu, and A.J. Zurita et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials Lancet Oncol 13 2012 827 837
25. T.K. Choueiri, S.A. Vaziri, and E. Jaeger et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma J Urol 180 2008 860 865 [discussion 5-6]
26. P. Kapur, S. Pena-Llopis, and A. Christie et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation Lancet Oncol 14 2013 159 167